IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0408900
(2003-04-08)
|
발명자
/ 주소 |
- Gow,Robert
- Pierce,John
- Pierce,Brian
- Birdsall,William
|
출원인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
48 |
초록
▼
The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pha
The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.
대표청구항
▼
We claim: 1. A method for enhancing the efficacy of an active ingredient in a human comprising, administering to said human in need thereof a product comprising; a kavalactone component and an active ingredient, wherein the kavalactone component comprises, by mass, less than about 15% of a combinat
We claim: 1. A method for enhancing the efficacy of an active ingredient in a human comprising, administering to said human in need thereof a product comprising; a kavalactone component and an active ingredient, wherein the kavalactone component comprises, by mass, less than about 15% of a combination of methysticin and dihydromethysticin, less than about 8% of a combination of yangonin and desmethoxyyangonin, and greater than about 70% of a combination of kavain and dihydrokavain, wherein the kavalactone component is between about 0.1% to about 75% by mass of said product, and wherein the active ingredient is methylsulfonylmethane, acetylsalicylic acid, NSAIDSs, ibuprofen, acetaminophen, nitrous oxide, benzocaine, procaine, lidocaine, anesthetics, halothane, thorazine, vesprin, prolixin, opoid analgesics and antagonists, morphine, codeine or oxycodone. 2. The method of claim 1, wherein said kavalactone component is present in an amount from about 5 to about 35%, by mass, of said product. 3. The method of claim 1 wherein said product is a dry flowable powder. 4. The method of claim 1 wherein said product is a paste extract. 5. The method of claim 1 wherein said product is a liquid extract. 6. The method of claim 1 wherein said product is a rapid dissolve tablet. 7. The method of claim 1, wherein the dihydromethysticin component is less than about five percent by weight of said kavalactone component. 8. The method of claim 1, wherein the desmethoxyyangonin component is less than about four percent by weight of said kavalactone component. 9. The method of claim 1, wherein the yangonin component is less than about one percent by weight of said kavalactone component. 10. The method of claim 1, wherein the dihydrokavain component is greater than about fifty percent by weight of said kavalactone component. 11. The method of claim 1, wherein the kavain component is greater than about thirty-eight percent by weight of said kavalactone component. 12. The method of claim 1, wherein the dihydromethysticin component is less than about five percent by weight of said kavalactone component, the desmethoxyyangonin component is less than about four percent by weight of said kavalactone component, the yangonin component is less than about one percent by weight of said kavalactone component, the dihydrokavain component is greater than about fifty percent by weight of said kavalactone component, and the kavain component is greater than about thirty-eight percent by weight of said kavalactone component.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.